HPV vaccine, its preparation method and application

By designing an HPV vaccine containing HPV type 16 E6-E7 fusion protein, HPV type 18 E6-E7 fusion protein, HPV type 16-18 E2 fusion protein, and HPV E1 protein, a CTL cell immune response is stimulated, solving the problem of the lack of effective therapeutic HPV vaccines in the existing technology and achieving effective clearance of HPV infection and early lesions.

CN122399005APending Publication Date: 2026-07-17CHENGDU MAXVAX BIOTECHNOLOGY LLC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
CHENGDU MAXVAX BIOTECHNOLOGY LLC
Filing Date
2025-01-10
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Current technology lacks effective therapeutic HPV vaccines, making it impossible to effectively treat individuals already infected with HPV and exhibiting precancerous lesions.

Method used

An HPV vaccine was designed, comprising HPV 16 E6-E7 fusion protein, HPV 18 E6-E7 fusion protein, HPV 16-18 E2 fusion protein, and HPV E1 protein. Through specific amino acid sequence optimization and combination, and with specific adjuvants, it stimulates CTL cell immune response and clears early lesions associated with HPV infection.

Benefits of technology

This HPV vaccine has excellent immunogenicity, and can activate antigen-specific cellular immunity against E1, E2, E6 and E7 proteins, clear persistent HPV infection and prevent further disease progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122399005A_ABST
    Figure CN122399005A_ABST
Patent Text Reader

Abstract

本发明公开了一种HPV疫苗及其制备方法和应用，涉及医药领域，本发明通过将靶向抗原HPV E1、E2、E6和E7进行组合，并进行了序列优化，获得了治疗性的HPV疫苗，该HPV疫苗具有优异的免疫原性，有助于有效清除病毒以及与HPV感染相关的早期病变，适用范围广泛。
Need to check novelty before this filing date? Find Prior Art